Bronchial Spasms – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Bronchial spasm, or bronchospasm, refers to the abnormal contraction of bronchial smooth muscles when exposed to various stimuli like allergens or irritants. This leads to the narrowing and blockage of the airways. Factors such as mechanical or chemical irritants and underlying airway hyperactivity, as seen in upper airway tract infections and smoking, can often trigger this condition. Several factors can induce bronchospasm, including airway irritation, anaphylaxis, aspiration, pulmonary edema, allergies, acute asthma exacerbation, a wrongly positioned endotracheal tube, or issues during extubation. Signs and symptoms of bronchospasm encompass expiratory wheezes, skin rash, elevated peak airway pressure, desaturation (reduced oxygen levels), increased EtCO2 (end-tidal carbon dioxide levels), and a distinctive 'shark-fin' appearance on the capnogram. Differential diagnosis should include endobronchial intubation, airway foreign bodies, mucus blockages, kinks in the circuit or endotracheal tube, pulmonary aspiration, and the occlusion of the tracheal/bronchial passage by the endotracheal tube cuff. Furthermore, bronchospasm might be the initial indicator of anaphylaxis. Management of bronchospasm typically involves bronchodilators. For more severe cases, steroids are employed to decrease airway inflammation. The treatment options include:

  • Short-Acting Bronchodilators: Terbutaline, Salbutamol, and Levosalbutamol are commonly used to relieve symptoms rapidly. These bronchodilators widen the airways within minutes, and their effects persist for up to six hours.
  • Long-Acting Bronchodilators: Formoterol and Salmeterol are frequently prescribed for long-term control. They don't provide immediate relief, but their effects last around 12 hours. Another type of long-acting bronchodilator includes anticholinergic agents, available in short-acting (Ipratropium) and long-acting (Tiotropium, Umeclidinium, and Aclidinium) forms.
  • Steroids: Inhaled steroids are administered to reduce airway inflammation. In severe bronchospasm cases, intravenous steroids may be necessary for treatment.

Thelansis’s “Bronchial Spasms Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchial Spasms treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Bronchial Spasms across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Bronchial Spasms Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Bronchial Spasms – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more